Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.58 |
| ▸ | FNTB | P49356 | 14/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28782663 | 0.89 | FNTA (0.72) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL2844704 | 0.89 | FNTA (0.72) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL4281997 | 0.86 | FNTA (0.60) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL4285788 | 0.86 | FNTA (0.60) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL4284855 | 0.81 | FNTA (0.48) | FNTAFNTBPGGT1BCNR1RORC | |
| SCHEMBL1682751 | 0.80 | FNTA (0.61) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL4278951 | 0.79 | FNTA (0.55) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL4276938 | 0.77 | FNTA (0.61) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL4282437 | 0.77 | FNTA (0.51) | FNTAFNTBPGGT1BCYP3A4CNR1 | |
| SCHEMBL6169281 | 0.76 | FNTA (0.79) | FNTAFNTBPGGT1BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | claimed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | FNTA 855/4885FNTB 2166/4885PGGT1B 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.